Browse result page of AntiTbPdb
The total number entries retrieved from this search are 54
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1132 | Human neutrophil defensin (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Internal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29) | Cyclic | 30 | L | Cationic | Protein Derived | From the human defensin protein found in granules of neutrophils. | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 25618) | 50 mg/L causes approx 70 % growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1133 | Human neutrophil defensin (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Internal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29) | Cyclic | 30 | L | Cationic | Protein Derived | From the human defensin protein found in granules of neutrophils. | Mycobacterium tuberculosis | Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain | 50 mg/L causes approx 30 % growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1136 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Free | Amidation | None | Linear | 27 | L | Cationic | Protein Derived | Core region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 17.5 μg of NK-2/ml killed >90% M. smegmatis population after 24 h of incubation | In vitro | RAW264.7 | No significant reduction in intracellular survival of M. smegmatis was observed | No significant reduction in cell viability upto 100 μg/ml | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | None | Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans) | 2013 | 23689720 |
| antitb_1137 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Free | Amidation | None | Linear | 27 | L | Cationic | Protein Derived | Core region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 7 μg of NK- 2/ml combined with 0.5 ppm of NP-1 kills 90% of M. smegmatis | In vitro | RAW264.7 | Combination of NP-1 and NK-2 showed 35% reduction in intracellular survival of M. smegmatis | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | AgNPs synthesiszed only in the presence of a plant Alstonia macrophylla (NP-1). | Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans) | 2013 | 23689720 |
| antitb_1138 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Free | Amidation | None | Linear | 27 | L | Cationic | Protein Derived | Core region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 7 μg of NK- 2/ml combined with 0.5 ppm of NP-2 kills 90% of M. smegmatis | In vitro | RAW264.7 | NP-2 in combination with NK-2 killed >52% intra- cellular M. smegmatis. | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | AgNPs synthesiszed only in the presence of a fungal Trichoderma sp. (NP-2). | Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans) | 2013 | 23689720 |
| antitb_1139 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Free | Amidation | None | Linear | 27 | L | Cationic | Protein Derived | Core region of the lymphocytic effector protein NK-lysin, found in NK cells and cytotoxic T cells | Mycobacterium marinum | Mycobacterium marinum (ATCC 927) | IC90 = 3.5 μg/ml | In vitro | RAW264.7 | Moderate killing was observed | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | None | Antibacterial, Antiprotozoan (Trypanosoma cruzi and Plasmodium falciparum) and antifungal (Candida albicans) | 2013 | 23689720 |
| antitb_1189 | Pin2 [GPG] | FWGALAKGALKLIGPGSLFSSFSKKD | Free | Free | None | Linear | 26 | L | Cationic | Synthetic | Amino acid substitution at one postion of Pin2 (P at 14 by GPG) | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 80.1 ± 24.8 μg/ml or 29 ± 9 μM | In vitro | RBC | NA | Hemolysis ( IC-50 = 46.6 [34–64] ) | None | NA | NA | Cell wall disruption | Cell wall | None | Anti-bacterial (E. coli, S. aureus) | 2014 | 25019413 |
| antitb_1190 | Pin2 [GPG] | FWGALAKGALKLIGPGSLFSSFSKKD | Free | Free | None | Linear | 26 | L | Cationic | Synthetic | Amino acid substitution at one postion of Pin2 (P at 14 by GPG) | Mycobacterium tuberculosis | Mycobacterium tuberculosis muti-drug resistant strain (MDR) clinical isolate | MIC = 48.1 μg/ml or 17.4 μM | In vitro | RBC | NA | Hemolysis ( IC-50 = 46.6 [34–64] ) | None | NA | NA | Cell wall disruption | Cell wall | None | Anti-bacterial (E. coli, S. aureus) | 2014 | 25019413 |
| antitb_1223 | Human neutrophil peptide 1 (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulfide bridge: 2-30, 4-19, 9-29 | Cyclic | 30 | L | NA | Protein Derived | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | 96.5 % inhibition at 10 μg/ml | In vitro | THP-1 cells | Significant reduction in CFU | NA | None | NA | NA | NA | NA | None | None | 2013 | 23827033 |
| antitb_1224 | Human neutrophil peptide 1 (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulfide bridge: 2-30, 4-19, 9-30 | Cyclic | 30 | L | NA | Protein Derived | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | 98.3 % inhibition at 15 μg/ml | In vitro | THP-1 cells | Significant reduction in CFU | NA | None | NA | NA | NA | NA | None | None | 2013 | 23827033 |
| antitb_1225 | Human neutrophil peptide 1 (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulfide bridge: 2-30, 4-19, 9-31 | Cyclic | 30 | L | NA | Protein Derived | Human neutrophil | Mycobacterium tuberculosis | 36 Clinical isolates of Mycobacterium tuberculosis | 11 isolates (31%) showed greater sensitivity to HNP-1 than H37Rv strains. At 15 μg/ml, they wer completely inhibited. | In vitro | THP-1 cells | Sixteen clinical isolates had lower intracellular growth ability than the H37Rv strain. | NA | None | NA | NA | NA | NA | None | None | 2013 | 23827033 |
| antitb_1226 | Human neutrophil peptide 1 (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulfide bridge: 2-30, 4-19, 9-32 | Cyclic | 30 | L | NA | Protein Derived | Human neutrophil | Mycobacterium bovis | Mycobacterium bovis BCG | 99.6 % inhibition at 10 μg/ml | In vitro | THP-1 cells | Significant reduction in CFU | NA | None | NA | NA | NA | NA | None | None | 2013 | 23827033 |
| antitb_1227 | Human neutrophil peptide 1 (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulfide bridge: 2-30, 4-19, 9-33 | Cyclic | 30 | L | NA | Protein Derived | Human neutrophil | Mycobacterium bovis | Mycobacterium bovis BCG | 100 % inhibition at 10 μg/ml | In vitro | THP-1 cells | Significant reduction in CFU | NA | None | NA | NA | NA | NA | None | None | 2013 | 23827033 |
| antitb_1264 | Cecropin A-melittin (CA-M) hybrid peptide | KWKLFKKIGIGAVLKVLTTGLPALIS | Free | Amidation | None | Linear | 26 | L | Cationic | Protein Derived | Hybrid derived from cecropin A-melittin | Mycobacterium vaccae | Mycobacterium vaccae strain (ATCC 15483) | MIC = 20.0 ± 1.0 μM | In vitro | None | NA | NA | None | NA | NA | Membrane depolarization and permeabilization | Cell envelope | None | Antibacterial and Antiparasitic | 2013 | 23716047 |
| antitb_1265 | Cecropin A-melittin (CA-M) hybrid peptide | KWKLFKKIGIGAVLKVLTTGLPALIS | Free | Amidation | None | Linear | 26 | L | Cationic | Protein Derived | Hybrid derived from cecropin A-melittin | Mycobacterium vaccae | Mycobacterium vaccae strain (ATCC 15483) | IC50 = 10.3 ± 0.3 μM | In vitro | None | NA | NA | None | NA | NA | Membrane depolarization and permeabilization | Cell envelope | None | Antibacterial and Antiparasitic | 2013 | 23716047 |
| antitb_1287 | Bcn1Â | FVYGNGVTSILVQAQFLVNGQRRFFYTPDK | Free | Free | None | Linear | 30 | L | NA | Natural | Isolated from diverse Gram-positive bacteria species | Mycobacterium tuberculosis | Mycobacterium tuberculosis strain H37Rv | MIC90 = 0.1 mg/L | Both | Mouse macrophages | No inhibition | No cytotoxicty | None | NA | NA | Formation of pores in cell membranes | Cell envelope | None | None | 2007 | 17347179 |
| antitb_1306 | D-(V13K) D1 | KWKSFLKTFKSAKKTVLHTALKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 70.7 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 421.5 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1307 | D-(V13K,A20L) D2 | KWKSFLKTFKSAKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 83.7 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 83 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1308 | D-(V13K,A12L,A20L) D3 | KWKSFLKTFKSLKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 109.2 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 14 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1309 | D-(V13K,A12L,A20L,A23L) D4 | KWKSFLKTFKSLKKTVLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 200 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 3.5 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1310 | D-(V13K,A12L,A20L,A23L,V16K) D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 35.2 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 47 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1311 | D-(V13K) D1 | KWKSFLKTFKSAKKTVLHTALKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 57 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 7.4 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1312 | D-(V13K,A20L) D2 | KWKSFLKTFKSAKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 72 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 12 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1313 | D-(V13K,A12L,A20L) D3 | KWKSFLKTFKSLKKTVLHTLLKAISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 100 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 0.14 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1314 | D-(V13K,A12L,A20L,A23L) D4 | KWKSFLKTFKSLKKTVLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = Ie μg/mL(inactive) | In vitro | Human erythrocyte | NA | HC50 = Ie μg/mL(inactive) | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1315 | D-(V13K,A12L,A20L,A23L,V16K) D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 26 | L | Cationic | Synthetic | NA | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv multidrug resistant strain vertulo | MIC = 49 μg/mL | In vitro | Human erythrocyte | NA | HC50 = 1.0 μg/mL | NA | NA | NA | NA | NA | NA | NA | 2011 | 20858205 |
| antitb_1355 | NKLF1 | VTQAASRVCDKMKILRGVCKKIMRTFLRR | Free | Free | Internal disulphide bond at residue between 9-13 | Cyclic | 29 | L | NA | Natural | Pig cytolytic lymphocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv ATCC 25619 | IC90 = 30 μM | In vitro | Human erythroleukaemia cell line K562 | NA | 31 % cytolytic activity in range of 3 -7 μM peptide concentration | NA | NA | NA | NA | NA | NA | Antibacterial against bacillus megaterium, E.coli, P.aeuroginosaand S.aureus | 1999 | 10585872 |
| antitb_1358 | Gran F1 | VSNAATRVCRTGRSRWRDVCRNFMRRYQSR | Free | Free | None | Linear | 30 | L | NA | Natural | Human cytolytic lymphocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv ATCC 25622 | IC90 = 30 μM | In vitro | Human erythroleukaemia cell line K562 | NA | 34 % cytolytic activity in range of 3 -7 μM peptide concentration | NA | NA | NA | NA | NA | NA | Antibacterial against bacillus megaterium, E.coli, P.aeuroginosaand S.aureus | 1999 | 10585872 |
| antitb_1370 | Human neutrophil peptides-1 | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | cyclic | 30 | L | Cationic | Synthetic | Human neutrophils | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37 Ra | NA | in vitro | None | NA | NA | NA | NA | NA | NA | Mycobacterial genomic DNA | NA | antibacterial against candida albicans | 2000 | 11375668 |
| antitb_1527 | Human neutrohil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | cyclic | 30 | L | Cationic | Synthetic | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | NA | in vitro | NA | NA | NA | NA | NA | Inteacting with microbial membrane | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25681127 | |
| antitb_1530 | D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 27 | L | Cationic | Protein derived | Derived from Human cationic antimicrobial protein 18 (hCAP18) | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 35.2 μg/ml | in vitro | Human macrophage THP1 | NA | No cytotoxicity | NA | NA | Induce expression of IL-8and MCP-1 | In vitro binding of bacterilamembrane and induce pore formation while in vivo activate TLR and monocyte to kill bacteria | Bacterial cell membrane | NA | NA | 2015 | 25613372 |
| antitb_1531 | D5 | KWKSFLKTFKSLKKTKLHTLLKLISS | Acetylation | Amidation | None | Linear | 27 | L | Cationic | Protein derived | Derived from Human cationic antimicrobial protein 18 (hCAP18) | Mycobacterium tuberculosis | Mycobacterium tuberculosis MDR-TB | MIC = 49 μg/ml | in vitro | Human macrophage THP1 | NA | No cytotoxicity | NA | NA | Induce expression of IL-8and MCP-1 | In vitro binding of bacterilamembrane and induce pore formation while in vivo activate TLR and monocyte to kill bacteria | Bacterial cell membrane | NA | NA | 2015 | 25613372 |
| antitb_1535 | Human neutrohil peptide (HNP-1) | DCYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | 2.5 μg/ml | in vitro | NA | NA | No cytotoxicity | NA | NA | Mediate macrophage to induce TNF-α expression | Inhibit lipid biosynthesi | NA | NA | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25613372 |
| antitb_1536 | Human neutrohil peptide (HNP-1) | DCYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50=0.0375 μg/ml | in vitro | NA | NA | NA | NA | NA | Mediate macrophage to induce TNF-α expression | Inhibit lipid biosynthesi | NA | HNP-1 + Rifampicin | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25613372 |
| antitb_1537 | Human neutrohil peptide (HNP-1) | DCYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | IC50= 0.0255 μg/ml | in vitro | NA | NA | NA | NA | NA | Mediate macrophage to induce TNF-α expression | Inhibit lipid biosynthesi | NA | HNP-1 + Isoniazid | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas | 2015 | 25613372 |
| antitb_1550 | Lacticin 3147 | AA-(Dhb)-N-(Dhb)-FALADYWGNNGAWA-(Abu)-L-(Abu)-HEAMAWAK | Free | Free | Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid | Linear | 30 | L | Cationic | Natural | Derived from Lactococcus lactis | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Ra | IC90= 7.5 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1551 | Lacticin 3147 | AA-(Dhb)-N-(Dhb)-FALADYWGNNGAWA-(Abu)-L-(Abu)-HEAMAWAK | Free | Free | Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid | Linear | 30 | L | Cationic | Natural | Derived from Lactococcus lactis | Mycobacterium avium | Mycobacterium avium | IC90= 60 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1552 | Lacticin 3147 | AA-(Dhb)-N-(Dhb)-FALADYWGNNGAWA-(Abu)-L-(Abu)-HEAMAWAK | Free | Free | Dhb= Didehydroaminobutyric acid, Abu= 2-aminobutyric acid | Linear | 30 | L | Cationic | Natural | Derived from Lactococcus lactis | Mycobacterium Kansaii | Mycobacterium Kansaii | IC90= 15 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 2015 | 25613372 |
| antitb_1651 | Human neutrohil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Synthetic | Human neutrophil | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | IC50 = 0.8μg/ml | in vitro | murine macrophage-like cell line J744A.1 | NA | cytotoxic at above concentration 5 ug/ml | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 2016 | 10933095 |
| antitb_1652 | Human neutrohil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Synthetic | Human neutrophil | Mycobacterium Tuberculosis | Mycobacterium tuberculosis H37Rv | IC90 = 2.5 μg/ml | in vitro | murine macrophage-like cell line J744A.1 | NA | NA | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 2016 | 10933095 |
| antitb_1702 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis Ra 7632G | Reduction in CFU at 50 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 1996 | 8641802 |
| antitb_1703 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys30 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis Ra 9034G | Reduction in CFU at 50 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 1996 | 8641802 |
| antitb_1704 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys31 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium tuberculosis | Mycobacterium tuberculosis Ra 11170G | Reduction in CFU at 50 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | Microbial membrane disruption | NA | NA | NA | 1996 | 8641802 |
| antitb_1716 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 25291 | Reduction in CFU at 5 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 |
| antitb_1717 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 25291 | Reduction in CFU at 50 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 |
| antitb_1718 | Human neutrophil peptide (HNP-2) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys1-cys29, cys3-cys18,cys8-cys28 | 29 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 25291 | Reduction in bacterial load to 64 % at 5 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 | |
| antitb_1719 | Human neutrophil peptide (HNP-3) | DCYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 25291 | Reduction in bacterial load to 61 % 5 μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 | |
| antitb_1720 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain SJB | Reduction in CFU/well 91.8 ± 1.1 at peptide concentration 50μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 |
| antitb_1721 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 292524 | Reduction in CFU/well70.6 ± 0.6 at peptide concentration 50μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 |
| antitb_1722 | Human neutrophil peptide (HNP-1) | ACYCRIPACIAGERRYGTCIYQGRLWAFCC | Free | Free | Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29 | Cyclic | 30 | L | Cationic | Natural | Human neutrophil | Mycobacterium avium- mycobacterium intracellularae | Mycobacterium avium- mycobacterium intracellularae strain 475049 | Reduction in CFU/well 32.5 ± 10.7 at peptide concentration 50μg/ml | in vitro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1992 | 1398982 |